Atika Capital Management’s Sage Therapeutics SAGE Stock Holding History

Atika Capital Management’s Portfolio SAGE Stock Details SAGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-38,500	Closed	-$7.05M	–	86
2019 Q2	$7.05M	Buy	+38,500	New	+$6.57M	1.38%	29
2018 Q2	–	Sell	-21,500	Closed	-$3.46M	–	105
2018 Q1	$3.46M	Buy	21,500 +15,500	+258%	+$2.63M	1.19%	35
2017 Q4	$988K	Buy	+6,000	New	+$582K	0.38%	63
2017 Q3	–	Sell	-7,000	Closed	-$550K	–	90
2017 Q2	$557K	Sell	7,000 -2,000	-22%	-$145K	0.2%	75
2017 Q1	$639K	Buy	+9,000	New	+$527K	0.31%	59
2016 Q1	–	Sell	-8,000	Closed	-$467K	–	58
2015 Q4	$467K	Buy	+8,000	New	+$396K	0.24%	51
2015 Q3	–	Sell	-33,000	Closed	-$2.41M	–	76
2015 Q2	$2.41M	Buy	+33,000	New	+$2.12M	1.08%	40

Other funds holding SAGE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Atika Capital Management's SAGE Position: Q3 2019 in Review

Atika Capital Management sold out of Sage Therapeutics (SAGE) in Q3 2019, closing a stake of 38,500 shares — an estimated $7.05M sold.

Atika Capital Management first reported a position in SAGE in Q2 2015 and held it in 7 quarters. The position peaked at $7.05M in Q2 2019. 284 funds tracked by Wall St. Rank hold SAGE as of Q3 2019.

Atika Capital Management reported no remaining Sage Therapeutics position as of Q3 2019 after selling out during the quarter.
Atika Capital Management sold 38,500 Sage Therapeutics shares in Q3 2019, an estimated $7.05M.
Atika Capital Management first reported a position in Sage Therapeutics in Q2 2015 and held it in 7 quarters.
Atika Capital Management's Sage Therapeutics position peaked at $7.05M in Q2 2019.
284 funds tracked by Wall St. Rank held Sage Therapeutics as of Q3 2019.

Based on Atika Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.